Monash University researchers have discovered a potential link between beta blockers and slowing the progression of triple negative breast cancer (TNBC). The study found that a molecular biomarker, HOXC12, can help determine which patients may benefit from beta blocker therapy at the time of diagnosis.
When stress hormones are released by the nervous system, they activate the ‘beta-2 adrenoceptor’, which accelerates cancer spread. Beta blockers, commonly prescribed to block stress hormone effects, have shown promise as a potential therapeutic option for TNBC patients.
Researchers used gene-editing tool CRISPR-Cas9 to delete HOXC12, disrupting the beta-2-adrenoceptor-cAMP-calcium interplay. The study suggests that HOXC12 is the key to identifying patients who will benefit from beta blocker therapy.
The discovery has exciting implications for TNBC treatment. Previous studies have shown a link between beta blockers and reduced mortality in people with TNBC, but the exact reason behind this effect was unknown. This new research provides a clearer understanding of how beta blockers can work against TNBC.
Further analysis of patient genomic data found that high levels of HOXC12 expression were associated with poorer overall survival. The researchers believe that HOXC12 could be used to identify patients who will benefit from beta blocker therapy, potentially leading to improved survival outcomes.
Source: https://retailpharmacymagazine.com.au/beta-blockers-show-promise-in-slowing-triple-negative-breast-cancer-study-shows